CTI BioPharma (CTIC) : 1 days before expiry, shorts in CTI BioPharma (CTIC) have reduced from 1,097,967 on Jul 29, 2016, to 602,983 on August 15, 2016. On an average, 674,373 shares are traded on the exchange. The outstanding bearish positions are equal to 0.2% of the float. Short sellers have covered -494,984 shares, a reduction of -45.1%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
CTI BioPharma (NASDAQ:CTIC): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.35 and $0.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.38. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.35, notching a gain of 0.25% for the day. The total traded volume was 937,804 . The stock had closed at $0.35 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Bianco James A, director officer (President and CEO) of Cti Biopharma Corp, had unloaded 10,000 shares at an average price of $0.37 in a transaction dated on June 24, 2016. The total value of the transaction was worth $3,700.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.